NASDAQ:SGMO - Sangamo Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $20.20
  • Forecasted Upside: 75.20 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$11.53
▲ +0.22 (1.95%)
1 month | 3 months | 12 months
Get New Sangamo Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGMO

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$20.20
▲ +75.20% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is $20.20, with a high forecast of $29.00 and a low forecast of $11.00. The average price target represents a 75.20% upside from the last price of $11.53.
Buy
The current consensus among 6 investment analysts is to buy stock in Sangamo Therapeutics. This rating has held steady since October 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/28/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/3/2021Wells Fargo & CompanyLower Price TargetOverweight$36.00 ➝ $29.00High
i
1/5/2021Stifel NicolausInitiated CoverageHold$16.00N/A
i
12/16/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by P. Trucchio at HC Wainwright
9/8/2020Bank of AmericaInitiated CoverageBuy$20.00Low
i
7/7/2020SunTrust BanksInitiated CoverageBuyHigh
i
6/22/2020HC WainwrightLower Price TargetBuy$16.00 ➝ $14.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/19/2020WedbushReiterated RatingHold$11.00Medium
i
Rating by Liana Moussatos at Wedbush
6/10/2020WedbushReiterated RatingHold$11.00High
i
Rating by Liana Moussatos at Wedbush
3/4/2020WedbushReiterated RatingHold$10.00High
i
Rating by Liana Moussatos at Wedbush
3/2/2020HC WainwrightReiterated RatingBuy$16.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/23/2019HC WainwrightReiterated RatingBuy$16.00High
i
Rating by D. Chattopadhyay at HC Wainwright
12/18/2019WedbushReiterated RatingHold$11.00Medium
i
Rating by Liana Moussatos at Wedbush
12/11/2019WedbushReiterated RatingHold$11.00Low
i
Rating by Liana Moussatos at Wedbush
12/9/2019CowenReiterated RatingBuyHigh
i
11/12/2019WedbushReiterated RatingHold$11.00Low
i
Rating by Liana Moussatos at Wedbush
8/26/2019HC WainwrightInitiated CoverageBuy$16.00Medium
i
Rating by D. Chattopadhyay at HC Wainwright
7/8/2019WedbushSet Price TargetHold$11.00Medium
i
Rating by Liana Moussatos at Wedbush
6/23/2019WedbushSet Price TargetHold$11.00Medium
i
Rating by Liana Moussatos at Wedbush
5/14/2019WedbushSet Price TargetHold$11.00Medium
i
Rating by Liana Moussatos at Wedbush
3/10/2019WedbushSet Price TargetHold$10.00Medium
i
Rating by Liana Moussatos at Wedbush
11/19/2018WedbushSet Price TargetHold$11.00Low
i
Rating by Liana Moussatos at Wedbush
11/14/2018JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$35.00 ➝ $11.00High
i
11/9/2018GuggenheimDowngradeBuy ➝ Neutral$18.00High
i
Rating by Whitney Ijem at Guggenheim
10/9/2018GuggenheimInitiated CoverageBuy ➝ Buy$18.00High
i
8/9/2018WedbushReiterated RatingHold$10.00High
i
Rating by Liana Moussatos at Wedbush
7/24/2018WedbushReiterated RatingHold$9.00Medium
i
7/23/2018CowenReiterated RatingBuyLow
i
6/20/2018Bank of AmericaInitiated CoverageBuy$24.00High
i
3/13/2018WedbushReiterated RatingHold$8.00Medium
i
2/25/2018BarclaysReiterated RatingBuy$30.00Low
i
2/23/2018Jefferies Financial GroupReiterated RatingBuyLow
i
2/12/2018WedbushReiterated RatingNeutral$6.00High
i
1/3/2018Piper Jaffray CompaniesSet Price TargetBuy$25.00High
i
Rating by Charles Duncan at Piper Jaffray Companies
11/22/2017BarclaysInitiated CoverageOverweight$20.00N/A
i
11/15/2017WedbushReiterated RatingHold$6.00N/A
i
11/15/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$19.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
10/13/2017Jefferies Financial GroupReiterated RatingBuy$18.00N/A
i
9/14/2017Jefferies Financial GroupReiterated RatingBuy$18.00High
i
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform$20.00 ➝ $30.00Low
i
8/10/2017Piper Jaffray CompaniesSet Price TargetHold$8.00High
i
Rating by Charles Duncan at Piper Jaffray Companies
6/22/2017Jefferies Financial GroupReiterated RatingBuy ➝ Buy$17.00High
i
5/16/2017WedbushReiterated RatingNeutral$6.00 ➝ $4.00Medium
i
3/22/2017CowenReiterated RatingBuyHigh
i
3/1/2017WedbushReiterated RatingNeutral$4.00N/A
i
Rating by L. Moussatos at Wedbush
2/28/2017CowenReiterated RatingBuyN/A
i
2/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$5.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
2/8/2017WedbushReiterated RatingNeutral$4.00N/A
i
Rating by L. Moussatos at Wedbush
1/5/2017WedbushReiterated RatingNeutral$4.00N/A
i
Rating by L. Moussatos at Wedbush
11/1/2016WedbushDowngradeOutperform ➝ Neutral$30.00 ➝ $4.00N/A
i
Rating by L. Moussatos at Wedbush
10/19/2016Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$9.00 ➝ $5.00N/A
i
8/10/2016CowenReiterated RatingBuyN/A
i
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
8/4/2016Janney Montgomery ScottDowngradeBuy ➝ Neutral$15.00 ➝ $8.00N/A
i
6/9/2016Jefferies Financial GroupReiterated RatingBuy$14.00N/A
i
5/6/2016WedbushReiterated RatingOutperform$30.00N/A
i
Rating by Liana Moussatos at Wedbush
5/3/2016Wells Fargo & CompanyInitiated CoverageBuyN/A
i
Rating by Jim Birchenough at Wells Fargo & Company
(Data available from 4/21/2016 forward)
Sangamo Therapeutics logo
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $11.53
$11.15
$11.58

50 Day Range

MA: $11.79
$10.88
$13.59

52 Week Range

Now: $11.53
$7.52
$19.43

Volume

743,059 shs

Average Volume

1,494,301 shs

Market Capitalization

$1.66 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.97

Frequently Asked Questions

What sell-side analysts currently cover shares of Sangamo Therapeutics?

The following equities research analysts have issued research reports on Sangamo Therapeutics in the last twelve months: Bank of America Co., HC Wainwright, Stifel Nicolaus, SunTrust Banks, Inc., TheStreet, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for SGMO.

What is the current price target for Sangamo Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Sangamo Therapeutics in the last year. Their average twelve-month price target is $20.20, suggesting a possible upside of 77.2%. Wells Fargo & Company has the highest price target set, predicting SGMO will reach $29.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $11.00 for Sangamo Therapeutics in the next year.
View the latest price targets for SGMO.

What is the current consensus analyst rating for Sangamo Therapeutics?

Sangamo Therapeutics currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SGMO will outperform the market and that investors should add to their positions of Sangamo Therapeutics.
View the latest ratings for SGMO.

What other companies compete with Sangamo Therapeutics?

How do I contact Sangamo Therapeutics' investor relations team?

Sangamo Therapeutics' physical mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company's listed phone number is 510-970-6000 and its investor relations email address is [email protected] The official website for Sangamo Therapeutics is www.sangamo.com.